Adalimumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00051 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 38 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | rheumatoid vasculitis | KG + DL |
| 2 | hypermobility of coccyx | KG + DL |
| 3 | inflammatory spondylopathy | KG + DL |
| 4 | Kummell disease | KG + DL |
| 5 | polyarticular juvenile rheumatoid arthritis | KG + DL |
| 6 | vertebral disease | KG + DL |
| 7 | polyp of middle ear | KG + DL |
| 8 | polyp of vocal cord | KG + DL |
| 9 | polyp of ureter | KG + DL |
| 10 | polyp of frontal sinus | KG + DL |
| 11 | epulis | KG + DL |
| 12 | polyp of external auditory canal | KG + DL |
| 13 | polyp of vulva | KG + DL |
| 14 | uterine polyp | KG + DL |
| 15 | fibroepithelial polyp | KG + DL |
| 16 | neoplastic polyp | KG + DL |
| 17 | mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency | KG + DL |
| 18 | acne (disease) | KG + DL |
| 19 | rheumatoid nodulosis | KG + DL |
| 20 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | KG + DL |
| 21 | seborrheic dermatitis | KG + DL |
| 22 | zinc, elevated plasma | KG + DL |
| 23 | juvenile chronic polyarthritis | KG + DL |
| 24 | Smouldering systemic mastocytosis | KG + DL |
| 25 | lymphoadenopathic mastocytosis with eosinophilia | KG + DL |
| 26 | keratinization disease | KG + DL |
| 27 | fibroma | KG + DL |
| 28 | systemic mastocytosis | KG + DL |
| 29 | gingival hypertrophy | KG + DL |
| 30 | Behcet disease | KG + DL |
| 31 | congenital hypotrichosis with juvenile macular dystrophy | KG + DL |
| 32 | discitis | KG + DL |
| 33 | primary release disorder of platelets | KG + DL |
| 34 | infantile systemic hyalinosis | KG + DL |
| 35 | pseudo-von Willebrand disease | KG + DL |
| 36 | dermatitis | KG + DL |
| 37 | synovitis (disease) | KG + DL |
| 38 | autosomal dominant macrothrombocytopenia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.